CD276 and neoplasm: Multiple clinical trials targeting tumor antigens have been approved, including CEA, MSLN, EpCAM, HER2 and antigens, as well as NK group 2 member D ligands (NKG2DL), Mucin-1 (MUC1), B7-H3 (CD276), CD133, mesenchymal epithelial transfer factor(c-Met), which is overexpressed in colorectal cancer, can be used as a target for CAR-T cells.